ABBV-303 + budigalimab

ABBV-303 + budigalimab is an investigational combination therapy being studied for the treatment of advanced solid tumors, including relapsed or refractory non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), and other solid tumor types. ABBV-303 is a TriNKET-based immunotherapeutic, developed using Dragonfly's platform technology, designed to engage the immune system against cancer cells. Budigalimab (ABBV-181) is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as a checkpoint inhibitor to enhance anti-tumor immune responses. Both drugs are administered intravenously. The combination aims to harness both innate and adaptive immunity for potential improvement in cancer outcomes[1][2][3][5][6][7][9].